Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) is now available.
Zylox-Tonbridge Medical Technology has issued a positive profit alert, indicating that net profit attributable to shareholders for 2025 is expected to exceed RMB240 million, a year-on-year increase of about 139%, on revenues projected to surpass RMB1.05 billion, up roughly 35% from 2024. The company attributes this strong performance to robust domestic demand for its core neurovascular and vascular products, more than 100% growth in international sales driven by broader regional market penetration, and improved operational efficiency alongside stable gross margins, signalling accelerated scale-up of its business and strengthening competitive position in both China and overseas markets ahead of its final audited results due by end-March 2026.
The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a China-based medical device company focused on neurovascular and peripheral vascular interventions. Its flagship products include the Kylin Flow Diverter, Neurovascular Guidewire, UltraFree Drug-Coated PTA Balloon Catheter and the Swan Endovenous Radiofrequency Ablation Catheter, serving both the domestic Chinese market and an expanding international footprint.
Average Trading Volume: 722,075
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.57B
For a thorough assessment of 2190 stock, go to TipRanks’ Stock Analysis page.